Chris J. O'Callaghan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chris J. O'Callaghan has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Derek J. Jonker
Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
40 shared publications - Jonathan M. Loree
BC Cancer, Vancouver, BC, Canada
40 shared publications - Daniel John Renouf
Pancreas Centre BC, Vancouver, Canada
35 shared publications - Emma Titmuss
BC Cancer, Vancouver, BC, Canada
35 shared publications - Aly Karsan
BC Cancer and The University of British Columbia
30 shared publications - Eric Xueyu Chen
Princess Margaret Cancer Centre 4 Toronto, Ontario
30 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF9
Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Purpose: Pre-existing and emerging molecular targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clinical practice. Tumor profiling through circulating tumor DNA (ctDNA) represents an important opportunity in PDAC because of the aggressive nature of the disease. Circulating tumor fraction (CTF) levels are highly variable within and between cancer types and influence the accuracy of plasma-based tumor profiling, and the variability and factors related to CTF levels in PDAC are not well understood. Experimental Design: ctDNA sequencing (PredicineATLAS) and clinical metadata from a cohort of 166 patients with metastatic PDAC (mPDAC) were generated as part of the PA.7 trial (NCT02879318). Patients were stratified into high CTF (>30% CTF; 35/166, 21.08%) and low CTF (131/166, 78.92%) groups for comparative analysis. Matched RNA sequencing data were available for 20 patients. Results: High CTF was associated with lower overall survival (hazard ratio = 1.87; 95% confidence interval, 1.27–2.75; P = 0.0014) as well as clinical presentation that was indicative of higher disease burden, with CTF highest in patients that had liver metastases and distant metastases including bulky lymph nodes versus patients with no liver metastases (P < 0.001). Exploratory gene expression analysis revealed a positive association between CTF and upregulation of cell cycle–related pathways, which included those involving CDK4 (P = 0.0093) and MT2A (P = 0.012), as well as glycolytic (P = 0.0028) and basal-like (P = 0.029) subtyping genes. Conclusions: These data demonstrate the heterogeneity of CTF and its associated factors in mPDAC, which converge toward an aggressive phenotype from both clinical and molecular standpoints.
- 18 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF9
Open AccessClinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Purpose: Pre-existing and emerging molecular targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clinical practice. Tumor profiling through circulating tumor DNA (ctDNA) represents an important opportunity in PDAC because of the aggressive nature of the disease. Circulating tumor fraction (CTF) levels are highly variable within and between cancer types and influence the accuracy of plasma-based tumor profiling, and the variability and factors related to CTF levels in PDAC are not well understood. Experimental Design: ctDNA sequencing (PredicineATLAS) and clinical metadata from a cohort of 166 patients with metastatic PDAC (mPDAC) were generated as part of the PA.7 trial (NCT02879318). Patients were stratified into high CTF (>30% CTF; 35/166, 21.08%) and low CTF (131/166, 78.92%) groups for comparative analysis. Matched RNA sequencing data were available for 20 patients. Results: High CTF was associated with lower overall survival (hazard ratio = 1.87; 95% confidence interval, 1.27–2.75; P = 0.0014) as well as clinical presentation that was indicative of higher disease burden, with CTF highest in patients that had liver metastases and distant metastases including bulky lymph nodes versus patients with no liver metastases (P < 0.001). Exploratory gene expression analysis revealed a positive association between CTF and upregulation of cell cycle–related pathways, which included those involving CDK4 (P = 0.0093) and MT2A (P = 0.012), as well as glycolytic (P = 0.0028) and basal-like (P = 0.029) subtyping genes. Conclusions: These data demonstrate the heterogeneity of CTF and its associated factors in mPDAC, which converge toward an aggressive phenotype from both clinical and molecular standpoints.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Progression free survival for patients on PREDiCT-l, split by tumor type. Therapy received is indicated in each title above each Kaplan Meier curve.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Progression free survival for patients on PREDiCT-l, split by tumor type. Therapy received is indicated in each title above each Kaplan Meier curve.
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
All CHIP variants identified in the study
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
All CHIP variants identified in the study
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
VAF of all CHIP variants split by cohort
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
VAF of all CHIP variants split by cohort
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Data from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Clonal hematopoiesis of indeterminate potential (CHIP) is the clonal expansion of hematopoietic stem cells from somatic mutations. It is a common incidental finding in cell-free DNA (cfDNA). We investigated the incidence of CHIP in cfDNA from patients with solid tumors and explored its association with treatment outcomes and adverse events. We reviewed cfDNA results from a local prospective solid tumor cohort (PREDiCT-l) and two randomized trials: Canadian Cancer Trials Group CO.26 [durvalumab + tremelimumab (D + T) or best supportive care in metastatic colorectal cancer] and Canadian Cancer Trials Group PA.7 (gemcitabine and nab-paclitaxel ± D + T in metastatic pancreatic adenocarcinoma). CHIP+ was defined as any mutation in DNMT3A, TET2, or ASXL1 with a variant allele frequency ≥2%. Presumed germline variants (variant allele frequency >40%) were removed. The first line of treatment after cfDNA was reviewed for grade ≥3 and dose-limiting toxicities. The prevalence of CHIP in the 465 included patients was 10% to 30%, and it was more common as age increased (P = 0.003). DNMT3A was the gene most frequently mutated in all cohorts. Patients with CHIP in PA.7 treated with immunotherapy showed an improved progression-free survival versus CHIP− [HR = 0.55 (0.28–1.07); P = 0.079, P-interaction = 0.098 (multivariable)]. However, patients with CHIP treated with chemotherapy in PREDiCT-l showed a trend toward worse progression-free survival [HR = 1.82 (0.98–3.38); P = 0.059]. There was no difference in adverse event rates between CHIP ± groups for those treated with chemotherapy or immunotherapy. CHIP is common in patients with solid tumors. Although not appearing to affect rates of adverse events, CHIP may affect outcomes from immunotherapy or chemotherapy.Significance:Liquid biopsy is increasingly being used in oncology for tumor molecular characterization. CHIP is a common incidental finding in cfDNA, and its prevalence increases with age. This study builds on growing evidence of common CHIP variants in patients with solid tumors. The results suggest a possible clinical impact of CHIP on treatment outcomes from immunotherapy or chemotherapy. This may have implications for treatment selection for patients with solid tumors.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Clonal hematopoiesis of indeterminate potential (CHIP) is the clonal expansion of hematopoietic stem cells from somatic mutations. It is a common incidental finding in cell-free DNA (cfDNA). We investigated the incidence of CHIP in cfDNA from patients with solid tumors and explored its association with treatment outcomes and adverse events. We reviewed cfDNA results from a local prospective solid tumor cohort (PREDiCT-l) and two randomized trials: Canadian Cancer Trials Group CO.26 [durvalumab + tremelimumab (D + T) or best supportive care in metastatic colorectal cancer] and Canadian Cancer Trials Group PA.7 (gemcitabine and nab-paclitaxel ± D + T in metastatic pancreatic adenocarcinoma). CHIP+ was defined as any mutation in DNMT3A, TET2, or ASXL1 with a variant allele frequency ≥2%. Presumed germline variants (variant allele frequency >40%) were removed. The first line of treatment after cfDNA was reviewed for grade ≥3 and dose-limiting toxicities. The prevalence of CHIP in the 465 included patients was 10% to 30%, and it was more common as age increased (P = 0.003). DNMT3A was the gene most frequently mutated in all cohorts. Patients with CHIP in PA.7 treated with immunotherapy showed an improved progression-free survival versus CHIP− [HR = 0.55 (0.28–1.07); P = 0.079, P-interaction = 0.098 (multivariable)]. However, patients with CHIP treated with chemotherapy in PREDiCT-l showed a trend toward worse progression-free survival [HR = 1.82 (0.98–3.38); P = 0.059]. There was no difference in adverse event rates between CHIP ± groups for those treated with chemotherapy or immunotherapy. CHIP is common in patients with solid tumors. Although not appearing to affect rates of adverse events, CHIP may affect outcomes from immunotherapy or chemotherapy.Significance:Liquid biopsy is increasingly being used in oncology for tumor molecular characterization. CHIP is a common incidental finding in cfDNA, and its prevalence increases with age. This study builds on growing evidence of common CHIP variants in patients with solid tumors. The results suggest a possible clinical impact of CHIP on treatment outcomes from immunotherapy or chemotherapy. This may have implications for treatment selection for patients with solid tumors.